SPOTLIGHT: Trial failure hits Evolutec

The Times is reporting that Evolutec is being put up on the sales block following the failure of its lead candidate in a mid-stage trial. Researchers for the company said that rEV131 had failed to reduce inflammation in patients following cataract surgery. The company has a market capitalization of 4 million pounds sterling. Report